Crossmark

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity

Crossref DOI link: https://doi.org/10.1186/s40425-019-0504-5

Published Online: 2019-02-06

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miret, Juan J.

Kirschmeier, Paul

Koyama, Shohei

Zhu, Mingrui

Li, Yvonne Y.

Naito, Yujiro

Wu, Min

Malladi, Venkat S.

Huang, Wei

Walker, William

Palakurthi, Sangeetha

Dranoff, Glenn

Hammerman, Peter S.

Pecot, Chad V.

Wong, Kwok-Kin

Akbay, Esra A. https://orcid.org/0000-0002-4149-2529
Funding

Funding for this research was provided by:

Cancer Prevention and Research Institute of Texas (RR160080)

International Association for the Study of Lung Cancer

National Cancer Institute (CA195740, CA163896, CA205150, CA 196932, K08 CA163677, R01CA215075)
More Information

Article History

Received: 1 August 2018

Accepted: 9 January 2019

First Online: 6 February 2019

Ethics approval and consent to participate

: Human tissue specimen investigations were performed after approval by an institutional review board. Written informed consent was obtained on all patients.

: Not applicable.

: SP and WH are employees of Elstar Therapeutics. GD, and PSH are employees of Novartis Institutes for Biomedical Research.K.K.W. is a founder and equity holder of G1 Therapeutics and he has Consulting/Sponsored Research Agreements with AstraZeneca, Janssen, Pfizer, Array, Novartis, Merck, Takeda, TargImmune, Ono and BMS.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.